Interferon-β reduces proteinuria in experimental glomerulonephritis

Journal of the American Society of Nephrology

Volumn 18, Issue 11, 2007, Pages 2875-2884

  Satchell, Simon C ^a   Buchatska, Olena ^b   Khan, Sarah B ^b   Bhangal, Gurjeet ^b   Tasman, Candida H ^a   Saleem, Moin A ^a   Baker, Darren P ^b   Lobb, Roy R ^b   Smith, Jennifer ^b   Cook, H Terence ^c   Mathieson, Peter W ^a   Pusey, Charles D ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA1A INTERFERON; CREATININE; PUROMYCIN; RECOMBINANT BETA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; KIDNEY INJURY; MACROPHAGE; MALE; NEPHRITIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 35848935010     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006101104     Document Type: Article

References (33)

1. Friedman RM, Vogel SN: Interferons with special emphasis on the immune system. Adv Immunol 34: 97-140, 1983
2. Ling PD, Warren MK, Vogel SN: Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 135: 1857-1863, 1985
3. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 56: 727-777, 1987
4. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC: Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther 3: 27-32, 1997
5. Kato T, Kitaura M, Inaba K, Watanabe Y, Kawade Y, Muramatsu S: Suppression of macrophage Ia antigen expression by endogenous interferon-alpha/beta. J Interferon Res Spec No: 29-41, 1992
6. Noronha A, Toscas A, Jensen MA: Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 46: 145-153, 1993
7. Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR: Interferon-beta: A therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 16: 3264-3272, 2005
8. Popik W, Inglot AD: Combined action of interferons and transforming growth factor beta on the proliferation of human fibroblasts. Arch Immunol Ther Exp (Warsz) 39: 19-26, 1991
9. Duncan MR, Berman B: Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 79: 1318-1324, 1987
10. Azuma A, Li YJ, Abe S, Usuki J, Matsuda K, Henmi S, Miyauchi Y, Ueda K, Izawa A, Sone S, Hashimoto S, Kudoh S: Interferon-beta inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-beta and thrombospondin. Am J Respir Cell Mol Biol 32: 93-98, 2005
11. Tam FW, Smith J, Morel D, Karkar AM, Thompson EM, Cook HT, Pusey CD: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14: 1658-1666, 1999
12. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006
13. Satchell SC, Anderson KL, Mathieson PW: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15: 566-574, 2004
14. Kraus J, Ling AK, Hamm S, Voigt K, Oschmann P, Engelhardt B: Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 56: 192-205, 2004
15. Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, Sasaki M, Warren AC, Jawahar A, Cappell B, Alexander JS: Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 10: 299-307, 2003
16. da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, Whitty A, Hochman PS: Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: Understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 22: 173-188, 2002
17. Kuruganti PA, Hinojoza JR, Eaton MJ, Ehmann UK, Sobel RA: Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules-implications for multiple sclerosis. J Neuropathol Exp Neurol 61: 710-724, 2002
18. Yong VW: Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59: 802-808, 2002
19. Singh A, Satchell SC, Neal C, Mathieson PW: The human glomerular endothelial glycocalyx contributes to endothelial barrier function in vitro [Abstract]. J Am Soc Nephrol 17: 741, 2006
20. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002
21. Van Den Berg JG, Aten J, Chand MA, Claessen N, Dijkink L, Wijdenes J, Lakkis FG, Weening JJ: Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 11: 413-422, 2000
22. Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M: Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 33: 1142-1146, 1999
23. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C: Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 38: E35, 2001
24. Haas M, Jager U, Mayer G: Interferon alfa-2c and proteinuria in a patient with focal and segmental glomerulosclerosis. Lancet 349: 1147-1148, 1997
25. Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, Segawa C, Hisada Y, Kobayashi K: Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33: 1040-1048, 1999
26. Nakao K, Sugiyama H, Makino E, Matsuura H, Ohmoto A, Sugimoto T, Ichikawa H, Wada J, Yamasaki Y, Makino H: Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. Nephron 90: 498-500, 2002
27. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003
28. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, Chadban SJ: Prevalence of albuminuria in Australia: The AusDiab Kidney Study. Kidney Int Suppl S22-S24, 2004
29. Bhan AK, Schneeberger EE, Collins AB, McCluskey RT: Evidence for a pathogenic role of a cell-mediated immune mechanism in experimental glomerulonephritis. J Exp Med 148: 246-260, 1978
30. Arduini RM, Li Z, Rapoza A, Gronke R, Hess DM, Wen D, Miatkowski K, Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R, Chen LL, Chen L, Betzenhauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP: Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif 34: 229-242, 2004
31. Huang XR, Holdsworth SR, Tipping PG: Th2 responses induce humorally mediated injury in experimental anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 8: 1101-1108, 1997
32. Giaever I, Keese CR: Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A 88: 7896-7900, 1991
33. Kataoka N, Iwaki K, Hashimoto K, Mochizuki S, Ogasawara Y, Sato M, Tsujioka K, Kajiya F: Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion. Proc Natl Acad Sci U S A 99: 15638-15643, 2002